Published in Eur Urol on July 02, 2007
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl (2011) 1.51
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate (2014) 1.49
Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol (2010) 1.23
Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation. J Biol Chem (2012) 0.99
Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth. Integr Biol (Camb) (2012) 0.97
Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int (2010) 0.96
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol (2011) 0.96
Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol (2012) 0.91
DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene (2014) 0.90
A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology (2009) 0.88
Are strict vegetarians protected against prostate cancer? Am J Clin Nutr (2015) 0.86
Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression. J Cancer Sci Ther (2010) 0.83
Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.82
Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats. J Inflamm (Lond) (2011) 0.81
Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol (2016) 0.80
Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. J Inflamm (Lond) (2013) 0.80
LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese Population. Int J Mol Sci (2013) 0.78
Characterisation of the prostanoid receptor mediating inhibition of smooth muscle contractility in the rat prostate gland. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.78
Bee venom suppresses testosterone-induced benign prostatic hyperplasia by regulating the inflammatory response and apoptosis. Exp Biol Med (Maywood) (2015) 0.77
Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia. Prostate (2014) 0.77
The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. J Inflamm (Lond) (2015) 0.76
Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment. Mol Cancer (2016) 0.76
Statins and male sexual health: a retrospective cohort analysis. J Sex Med (2014) 0.75
Anti-Inflammatory and Antimicrobial Effects of a Novel Herbal Formulation (WSY-1075) in a Chronic Bacterial Prostatitis Rat Model. World J Mens Health (2016) 0.75
Detection of Trichomonas vaginalis in prostate tissue and serostatus in patients with asymptomatic benign prostatic hyperplasia. BMC Infect Dis (2016) 0.75
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. J Inflamm (Lond) (2016) 0.75
Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review. Int Braz J Urol (2016) 0.75
The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis. Exp Ther Med (2017) 0.75
Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience. Saudi Med J (2015) 0.75
Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis. Biochem Med (Zagreb) (2015) 0.75
Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol (2007) 3.26
Treatment of varicocele in subfertile men: The Cochrane Review--a contrary opinion. Eur Urol (2006) 2.18
Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol (2003) 2.17
Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models. Urology (2013) 2.07
Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol (2013) 1.60
Smoking as a risk factor for erectile dysfunction: data from the Andrology Prevention Weeks 2001-2002 a study of the Italian Society of Andrology (s.I.a.). Eur Urol (2005) 1.52
Prostate growth and inflammation. J Steroid Biochem Mol Biol (2007) 1.33
Thulium laser supported nephron sparing surgery for renal cell carcinoma. J Urol (2013) 1.28
Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res (2003) 1.27
Two-sided bulbar urethroplasty using dorsal plus ventral oral graft: urinary and sexual outcomes of a new technique. J Urol (2011) 1.20
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol (2011) 1.09
Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res (2010) 1.04
Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate (2009) 0.97
Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res (2006) 0.95
Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer (2014) 0.94
Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest (2010) 0.92
Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate (2007) 0.90
Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl (2013) 0.89
Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int (2010) 0.89
The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol (2011) 0.88
Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. J Urol (2009) 0.88
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int (2004) 0.85
Superselective embolization of bladder arteries in the treatment of intractable bladder haemorrhage. Int J Urol (2005) 0.85
Management of urethral stent failure for recurrent anterior urethral strictures. Eur Urol (2009) 0.85
Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate. Can Urol Assoc J (2010) 0.85
Supernumerary kidney laparoscopically treated. Can Urol Assoc J (2013) 0.85
Urethral pseudodiverticulum secondary to penile fracture and complete urethra dissection. Can Urol Assoc J (2013) 0.84
In vivo 3D neuroanatomical evaluation of periprostatic nerve plexus with 3T-MR Diffusion Tensor Imaging. Eur J Radiol (2013) 0.84
Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol (2009) 0.84
[Role of neuroendocrine cells in prostate cancer progression]. Urologia (2011) 0.83
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate (2003) 0.83
Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int (2009) 0.83
Pain in the upper anterior-lateral part of the thigh in women affected by endometriosis: study of sensitive neuropathy. Fertil Steril (2013) 0.82
Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress. J Urol (2012) 0.82
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol (2012) 0.82
Use of cyclooxygenase-2 inhibitor for prevention of urethral strictures secondary to transurethral resection of the prostate. Urology (2005) 0.81
2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation. Eur Radiol (2008) 0.81
Update on screening in prostate cancer based on recent clinical trials. Rev Recent Clin Trials (2011) 0.81
Bladder cancer: a simple model becomes complex. Curr Genomics (2012) 0.81
Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review. Can Urol Assoc J (2012) 0.81
p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? J Med Virol (2008) 0.81
New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials (2008) 0.80
Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR). Urol Oncol (2011) 0.80
Is DD3 a new prostate-specific gene? Anticancer Res (2003) 0.80
Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. Urology (2008) 0.80
Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery. Urol Oncol (2011) 0.80
Knotless "three-U-stitches" technique for urethrovesical anastomosis during laparoscopic radical prostatectomy. Int J Urol (2012) 0.80
Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve-sparing radical prostatectomy. J Sex Med (2012) 0.80
Incidental prostatic stromal tumor of uncertain malignant potential (STUMP): histopathological and immunohistochemical findings. Urologia (2012) 0.79
Extracorporeal shock wave therapy in the treatment of Peyronie's disease: long-term results. Arch Ital Urol Androl (2010) 0.79
Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int (2008) 0.79
Primary synovial sarcoma of the penis. J Urol (2002) 0.79
[Neuroendocrine target therapies for prostate cancer]. Urologia (2011) 0.79